BIIB Biogen
- 201.040
- -0.960-0.48%
- 201.040
- 0.0000.00%
Biogen News
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
Biogen Analyst Ratings
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $251
Mizuho Adjusts Biogen's Price Target to $251 From $277, Keeps Outperform Rating
Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $302
Needham Maintains Buy on Biogen, Lowers Price Target to $285
Buy Rating Affirmed for Biogen Amid Strong Core Performance and Strategic Growth Initiatives
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $250
Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $270
Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo
Biogen Analyst Ratings
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $215 to $300
Buy Rating Affirmed: Biogen's Growth Momentum and Strategic Developments Fuel Positive Outlook
Wedbush Adjusts Price Target on Biogen to $210 From $215
Truist Financial Keeps Their Buy Rating on Biogen (BIIB)
Optimistic Outlook on Biogen's Leqembi for Alzheimer's: Buy Rating Justified by EMA Prospects and Positive Long-Term Data
Buy Rating Affirmed for Biogen: Strong Financials and Promising Alzheimer's Drugs Drive Growth Outlook
RBC Raises Price Target on Biogen to $292 From $282
Analysis
Price Target
No Data
